Medication info
Empa Tablet 10 mg (Empagliflozin)

Empa Tablet 10 mg (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Light yellow round film-coated tablet
Packaging
PTP packaging - 30 tablets/PTP[10 tablets/PTPX3], PTP packaging - 10 tablets/PTP[10 tablets/PTPX1]
Approval status
Active

MFDS item code 202105614 · Approved 2021.07.29 · Insurance code 671807990

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 10 mg once daily, either as monotherapy or as add-on therapy with other glucose-lowering agents, such as insulin. If 10 mg once daily is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose on the same day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This medicine should not be used in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment is not recommended in patients aged 85 years or older because clinical experience in this age group is limited.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
View approved original text

This medicine is used as an adjunct to diet and exercise to help control blood sugar levels in adults with type 2 diabetes. It can be used alone or in combination with other medications. It effectively supports blood sugar management even when blood sugar levels are not adequately controlled. It can be safely used in patients with type 2 diabetes who have cardiovascular disease, with caution as necessary. Overall, this drug helps improve blood sugar control and aids in diabetes management.

How to take

Adult dose

The recommended dose of this medicine is 10 mg once daily, either as monotherapy or as add-on therapy with other glucose-lowering agents, such as insulin. If 10 mg once daily is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose on the same day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This medicine should not be used in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment is not recommended in patients aged 85 years or older because clinical experience in this age group is limited.

Precautions

This medicine should not be administered to certain patients. First, patients who are allergic to the active substance or any ingredients of this medication should avoid taking it. Also, it should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired kidney function, specifically those with a glomerular filtration rate of less than 30 mL/min/1.73m2, or those with end-stage renal disease or undergoing dialysis, should not take this medication. This drug contains lactose, so patients with genetic problems like lactose intolerance, galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take it. Caution is required when administering this medication to patients with mildly impaired kidney function. It is advised not to initiate this medication in patients with a glomerular filtration rate of less than 60 mL/min/1.73m2, and dosage adjustments or discontinuation may be needed in those already on it. Experience with this drug is limited in patients with heart failure, especially those with severe heart failure, so caution is warranted, and its use is not recommended in certain severe cases. Caution is necessary if this medication is taken in conjunction with insulin or sulfonylureas, as the risk of hypoglycemia may increase, possibly requiring dosage adjustments. Side effects such as hypoglycemia, genital infections, urinary tract infections, increased urination, decreased fluid volume, increased serum creatinine, among others, may occur during the use of this drug, thus symptoms should be carefully monitored. There is a risk of serious metabolic acidosis known as ketoacidosis, so if symptoms such as vomiting, abdominal pain, breathing difficulties, or malaise occur, immediate consultation with a healthcare professional is needed. Caution is required for the elderly, particularly those aged 75 and above, as the risk of hypotension or dehydration due to fluid loss may increase. This medication may also increase the risk of genital fungal infections; early treatment should be initiated if infection symptoms appear. Precautions should be taken when driving or operating machinery, particularly if combined with insulin due to the risk of hypoglycemia. It is not recommended for pregnant women, and it should be discontinued immediately if pregnancy is confirmed. During breastfeeding, as there is a possibility of this drug being secreted in breast milk, it is advisable to stop breastfeeding. Safety and efficacy in children and adolescents (under 18 years) have not been established, so it should not be used in this population. No specific toxic symptoms have been reported in cases of overdose; however, appropriate treatment may be needed based on clinical conditions. This medication must be kept out of the reach of children and transferring it to other containers is not beneficial for maintaining quality.

Side effects

  • Hypoglycemia
  • vulvovaginitis
  • balanitis
  • other genital infections
  • urinary tract infection
  • perineal necrosis
  • ketoacidosis
  • itching
  • rash
  • urticaria
Show 12 more
  • angioedema
  • decreased fluid volume
  • increased urination
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • elevated serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly closed container to avoid exposure to air or moisture and kept at room temperature between 1 and 30 degrees Celsius. Storing it in this manner helps maintain the drug's effectiveness.

Appearance and packaging

Appearance

Light yellow round film-coated tablet

Package unit

PTP packaging - 30 tablets/PTP[10 tablets/PTPX3], PTP packaging - 10 tablets/PTP[10 tablets/PTPX1]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.